Ticker
LYELCompany Name
LYELL IMMUNOPHARMA INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Market Capitalization | Net Cash Flow - Issuance (Purchase) of Equity Shares | Net Cash Flow - Issuance (Repayment) of Debt Securities | Net Cash Flow - Dividends & Other Cash Distributions | Shareholder Yield |
---|---|---|---|---|---|
6/30/2025 | $ 203.06M | $ 621K | $ 0 | $ 0 | -0.31% |
3/31/2025 | $ 119.49M | $ 1.3M | $ 0 | $ 0 | -1.09% |
12/31/2024 | $ 196.53M | $ 1.4M | $ 0 | $ 0 | -0.71% |
9/30/2024 | $ 340.65M | $ 1.85M | $ 0 | $ 0 | -0.54% |
6/30/2024 | $ 360.96M | $ 1.92M | $ 0 | $ 0 | -0.53% |
3/31/2024 | $ 647.55M | $ 2.3M | $ 0 | $ 0 | -0.36% |
12/31/2023 | $ 721.63M | $ 2.2M | $ 0 | $ 0 | -0.3% |
9/30/2023 | $ 566.71M | $ 2.27M | $ 0 | $ 0 | -0.4% |
6/30/2023 | $ 602.46M | $ 7.33M | $ 0 | $ 0 | -1.22% |
3/31/2023 | $ 604.05M | $ 8.54M | $ 0 | $ 0 | -1.41% |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
(-1 * CF - Equity -1 * CF - Dividends -1 * CF - Debt) / Market Cap
(=) Shareholder Yield
Shareholder Yield for LYELL IMMUNOPHARMA INC is calculated as follows: (-1 * CF - Equity [ $ -11.43M ] -1 * CF - Dividends [ $ 0 ] -1 * CF - Debt [ $ 0 ]) / Market Cap [ $ 0 ]
(=) Shareholder Yield [ 0% ]
Minimum
Mar 31, 2022
Maximum
Dec 31, 2023
Average
Median
filtered constituents | 3.48K |
---|---|
min | -33.43% |
max | 34.45% |
average | 0.58% |
median | 1.07% |
std | 11.12% |